Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
MedSIR
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Pfizer
Duke University
Hoffmann-La Roche
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Spanish Breast Cancer Research Group
Allarity Therapeutics
Spanish Breast Cancer Research Group
M.D. Anderson Cancer Center
University of Kansas Medical Center
Medical University of South Carolina
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca
Dana-Farber Cancer Institute
NeoImmuneTech
National Cancer Institute (NCI)
Radiation Therapy Oncology Group
Mayo Clinic
AstraZeneca
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Mayo Clinic
Daiichi Sankyo
Penn State University
Eisai Inc.
OHSU Knight Cancer Institute
AstraZeneca
City of Hope Medical Center
Mayo Clinic
Alliance for Clinical Trials in Oncology
Sanofi
Massachusetts General Hospital
City of Hope Medical Center
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
Mayo Clinic
Hoffmann-La Roche
Dana-Farber Cancer Institute
Medical College of Wisconsin
AstraZeneca
M.D. Anderson Cancer Center